BUZZ-美国银行将药品开发商 Schrodinger 的评级上调至 "买入 "后，该公司股价上涨

路透中文

Dec 16, 2025

BUZZ-<a href="https://laohu8.com/S/BAC">美国银行</a>将药品开发商 Schrodinger 的评级上调至 "买入 "后，该公司股价上涨

12月15日 - ** 药物开发商Schrodinger SDGR.O股价上涨约1%，报18.24美元

** 美国银行将股票评级从 "中性 "上调至 "买入

** 券商认为制药行业和研发支出的背景更为有利

** 最近的季度业绩凸显了在市场嘈杂声中的韧性，软件和药物发现收入一直高于华尔街预期

** 继续看好研发反弹，认为这将加速 SDGR 平台的采用，尽管近期制药预算压力已拖累软件部门的增长

** 9 家券商中有 3 家将该股评为 "买入 "或更高，4 家 "持有"，2 家券商将该股评为 "卖出 "或更高，PT 中值为 28 美元--数据由 LSEG 编制

** 截至上次收盘，该股今年累计下跌约 6

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2591621628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591621628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591621628?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-16 00:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591621628","market":"hk","top_or_hot":-1,"title":"BUZZ-美国银行将药品开发商 Schrodinger 的评级上调至 \"买入 \"后，该公司股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/BAC\">美国银行</a>将药品开发商 Schrodinger 的评级上调至 \"买入 \"后，该公司股价上涨</title></head><body><p><span>12月15日</span><span> - </span>** 药物开发商Schrodinger <span>SDGR.O</span>股价上涨约1%，报18.24美元</p><p>** 美国银行将股票评级从 \"中性 \"上调至 \"买入</p><p>** 券商认为制药行业和研发支出的背景更为有利</p><p>** 最近的季度业绩凸显了在市场嘈杂声中的韧性，软件和药物发现收入一直高于华尔街预期</p><p>** 继续看好研发反弹，认为这将加速 SDGR 平台的采用，尽管近期制药预算压力已拖累软件部门的增长</p><p>** 9 家券商中有 3 家将该股评为 \"买入 \"或更高，4 家 \"持有\"，2 家券商将该股评为 \"卖出 \"或更高，PT 中值为 28 美元--数据由 LSEG 编制</p><p>** 截至上次收盘，该股今年累计下跌约 6</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-美国银行将药品开发商 Schrodinger 的评级上调至 \"买入 \"后，该公司股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-美国银行将药品开发商 Schrodinger 的评级上调至 \"买入 \"后，该公司股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-12-16 00:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/BAC\">美国银行</a>将药品开发商 Schrodinger 的评级上调至 \"买入 \"后，该公司股价上涨</title></head><body><p><span>12月15日</span><span> - </span>** 药物开发商Schrodinger <span>SDGR.O</span>股价上涨约1%，报18.24美元</p><p>** 美国银行将股票评级从 \"中性 \"上调至 \"买入</p><p>** 券商认为制药行业和研发支出的背景更为有利</p><p>** 最近的季度业绩凸显了在市场嘈杂声中的韧性，软件和药物发现收入一直高于华尔街预期</p><p>** 继续看好研发反弹，认为这将加速 SDGR 平台的采用，尽管近期制药预算压力已拖累软件部门的增长</p><p>** 9 家券商中有 3 家将该股评为 \"买入 \"或更高，4 家 \"持有\"，2 家券商将该股评为 \"卖出 \"或更高，PT 中值为 28 美元--数据由 LSEG 编制</p><p>** 截至上次收盘，该股今年累计下跌约 6</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL15Y:1","article_id":"2591621628","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591621628","pubTimestamp":1765814695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4167":"医疗保健技术","SDGR":"Schrodinger Inc."},"translate_title":"BUZZ-Shares of drug developer Schrodinger rise after Bank of America upgraded the company to Buy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SDGR":0.9},"content_text":"BUZZ-美国银行将药品开发商 Schrodinger 的评级上调至 \"买入 \"后，该公司股价上涨12月15日 - ** 药物开发商Schrodinger SDGR.O股价上涨约1%，报18.24美元** 美国银行将股票评级从 \"中性 \"上调至 \"买入** 券商认为制药行业和研发支出的背景更为有利** 最近的季度业绩凸显了在市场嘈杂声中的韧性，软件和药物发现收入一直高于华尔街预期** 继续看好研发反弹，认为这将加速 SDGR 平台的采用，尽管近期制药预算压力已拖累软件部门的增长** 9 家券商中有 3 家将该股评为 \"买入 \"或更高，4 家 \"持有\"，2 家券商将该股评为 \"卖出 \"或更高，PT 中值为 28 美元--数据由 LSEG 编制** 截至上次收盘，该股今年累计下跌约 6(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}